Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.46 |
| ▸ | GSK3B | P49841 | 6/20 | 0.46 |
| ▸ | WNT1 | P04628 | 5/20 | 0.46 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.45 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.45 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 5/20 | 0.44 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14908549 | 0.88 | MAPK1 (0.46) | DYRK1AGSK3BWNT1IL2MET | |
| SCHEMBL13838556 | 0.85 | IL2 (0.44) | DYRK1AGSK3BWNT1STIM1ORAI1 | |
| SCHEMBL13838355 | 0.82 | DYRK1A (0.46) | DYRK1AGSK3BWNT1IL2CLK2 | |
| SCHEMBL13730842 | 0.81 | DYRK1A (0.48) | DYRK1AGSK3BWNT1IL2CLK2 | |
| SCHEMBL13838430 | 0.81 | DYRK1A (0.45) | DYRK1AGSK3BWNT1IL2CLK2 | |
| Hydrochloric Acid SCHEMBL15793362 | 0.81 | DYRK1A (0.47) | DYRK1AGSK3BWNT1IL2CLK2 | |
| SCHEMBL13838532 | 0.80 | DYRK1A (0.44) | DYRK1AGSK3BWNT1IL2CLK2 | |
| SCHEMBL13727775 | 0.79 | DYRK1A (0.43) | DYRK1AGSK3BWNT1IL2CLK2 | |
| SCHEMBL13838537 | 0.78 | DYRK1A (0.42) | DYRK1AGSK3BWNT1IL2CLK2 | |
| SCHEMBL13838356 | 0.75 | DYRK1A (0.46) | DYRK1AGSK3BWNT1METMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140242099-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242099-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242099-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013063385-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013063385-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140242099-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | DYRK1A 4257/4885GSK3B 1579/4885WNT1 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.